According to the research report, the global clinical trial supplies market size is expected to touch USD 4.9 Billion by 2032, from USD 2.61 Billion in 2022, growing with a significant CAGR of 6.51% from 2023 to 2032.
The clinical trial supplies report offers a comprehensive study of the current state expected at the major drivers, market strategies, and key vendors’ growth. The report presents energetic visions to conclude and study the market size, market hopes, and competitive surroundings. The research also focuses on the important achievements of the market, research & development, and regional growth of the leading competitors operating in the market. The current trends of the global clinical trial supplies in conjunction with the geographical landscape of this vertical have also been included in this report.
The report offers intricate dynamics about different aspects of the global clinical trial supplies market, which aids companies operating in the market in making strategic development decisions. The study also elaborates on significant changes that are highly anticipated to configure growth of the global clinical trial supplies during the forecast period. It also includes a key indicator assessment that highlights growth prospects of this market and estimates statistics related to growth of the market in terms of value (US$ Mn) and volume (tons).
Sample Link @ https://www.precedenceresearch.com/sample/2777
Report Scope of the Clinical Trial Supplies Market:
| Report Coverage | Details |
| Market Size in 2023 | USD 2.78 Billion |
| Market Size by 2032 | USD 4.9 Billion |
| Growth Rate from 2023 to 2032 | CAGR of 6.51% |
| Largest Market | North America |
| Fastest Growing Market | Asia Pacific |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | By Phases, By Services, By End User, and By Therapeutic Area |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America and Middle East & Africa |
This study covers a detailed segmentation of the global clinical trial supplies market, along with key information and a competition outlook. The report mentions company profiles of players that are currently dominating the global clinical trial supplies market, wherein various developments, expansions, and winning strategies practiced and implemented by leading players have been presented in detail.
Key Players
- Thermos Fischer Scientific, Inc.
- Sharp Packaging Services
- Catalent Pharma Solutions
- Piramal Pharma Solutions
- UDG Healthcare
- PAREXEL International Corporation
- Almac Group Ltd.
- Movianto GmbH
- Patheon, Inc.
- Biocair International Ltd.
- PCI Services
Market Segmentation
By Phases
- Phase I
- Phase II
- Phase III
- Phase IV
By Services
- Logistics & distribution
- Storage & Retention
- Supply Chain Management
- Packaging, labeling, and blinding
- Manufacturing
- Comparator sourcing
By End User
- Pharma & Biotech companies
- Contract Research Organization (CRO)
- Medical Device Companies
By Therapeutic Area
- Oncology
- CNS & mental disorders
- Cardiovascular
- Digestive disorders
- Infectious diseases
- Metabolic disorders
- Immunology
- Blood disorders
- Other therapeutic areas (dermatological disorders, rare diseases, ENT diseases, Nephrology)
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- The Middle East and Africa
Research Methodology
The research methodology adopted by analysts for compiling the global clinical trial supplies report is based on detailed primary as well as secondary research. With the help of in-depth insights of the market-affiliated information that is obtained and legitimated by market-admissible resources, analysts have offered riveting observations and authentic forecasts for the global market.
During the primary research phase, analysts interviewed market stakeholders, investors, brand managers, vice presidents, and sales and marketing managers. Based on data obtained through interviews of genuine resources, analysts have emphasized the changing scenario of the global market.
For secondary research, analysts scrutinized numerous annual report publications, white papers, market association publications, and company websites to obtain the necessary understanding of the global clinical trial supplies market.
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Clinical Trial Supplies Market
5.1. COVID-19 Landscape: Clinical Trial Supplies Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Clinical Trial Supplies Market, By Phases
8.1. Clinical Trial Supplies Market, by Phases, 2023-2032
8.1.1. Phase I
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Phase II
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. Phase III
8.1.3.1. Market Revenue and Forecast (2020-2032)
8.1.4. Phase IV
8.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Clinical Trial Supplies Market, By Services
9.1. Clinical Trial Supplies Market, by Services, 2023-2032
9.1.1. Logistics & distribution
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Storage & Retention
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Supply Chain Management
9.1.3.1. Market Revenue and Forecast (2020-2032)
9.1.4. Packaging, labeling, and blinding
9.1.4.1. Market Revenue and Forecast (2020-2032)
9.1.5. Manufacturing
9.1.5.1. Market Revenue and Forecast (2020-2032)
9.1.6. Comparator sourcing
9.1.6.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Clinical Trial Supplies Market, By End User
10.1. Clinical Trial Supplies Market, by End User, 2023-2032
10.1.1. Pharma & Biotech companies
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Contract Research Organization (CRO)
10.1.2.1. Market Revenue and Forecast (2020-2032)
10.1.3. Medical Device Companies
10.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global Clinical Trial Supplies Market, By Therapeutic Area
11.1. Clinical Trial Supplies Market, by Therapeutic Area, 2023-2032
11.1.1. Oncology
11.1.1.1. Market Revenue and Forecast (2020-2032)
11.1.2. CNS & mental disorders
11.1.2.1. Market Revenue and Forecast (2020-2032)
11.1.3. Cardiovascular
11.1.3.1. Market Revenue and Forecast (2020-2032)
11.1.4. Digestive disorders
11.1.4.1. Market Revenue and Forecast (2020-2032)
11.1.5. Infectious diseases
11.1.5.1. Market Revenue and Forecast (2020-2032)
11.1.6. Metabolic disorders
11.1.6.1. Market Revenue and Forecast (2020-2032)
11.1.7. Immunology
11.1.7.1. Market Revenue and Forecast (2020-2032)
11.1.8. Blood disorders
11.1.8.1. Market Revenue and Forecast (2020-2032)
11.1.9. Other therapeutic areas (dermatological disorders, rare diseases, ENT diseases, Nephrology)
11.1.9.1. Market Revenue and Forecast (2020-2032)
Chapter 12. Global Clinical Trial Supplies Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Phases (2020-2032)
12.1.2. Market Revenue and Forecast, by Services (2020-2032)
12.1.3. Market Revenue and Forecast, by End User (2020-2032)
12.1.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Phases (2020-2032)
12.1.5.2. Market Revenue and Forecast, by Services (2020-2032)
12.1.5.3. Market Revenue and Forecast, by End User (2020-2032)
12.1.5.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Phases (2020-2032)
12.1.6.2. Market Revenue and Forecast, by Services (2020-2032)
12.1.6.3. Market Revenue and Forecast, by End User (2020-2032)
12.1.6.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Phases (2020-2032)
12.2.2. Market Revenue and Forecast, by Services (2020-2032)
12.2.3. Market Revenue and Forecast, by End User (2020-2032)
12.2.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Phases (2020-2032)
12.2.5.2. Market Revenue and Forecast, by Services (2020-2032)
12.2.5.3. Market Revenue and Forecast, by End User (2020-2032)
12.2.5.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Phases (2020-2032)
12.2.6.2. Market Revenue and Forecast, by Services (2020-2032)
12.2.6.3. Market Revenue and Forecast, by End User (2020-2032)
12.2.6.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Phases (2020-2032)
12.2.7.2. Market Revenue and Forecast, by Services (2020-2032)
12.2.7.3. Market Revenue and Forecast, by End User (2020-2032)
12.2.7.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Phases (2020-2032)
12.2.8.2. Market Revenue and Forecast, by Services (2020-2032)
12.2.8.3. Market Revenue and Forecast, by End User (2020-2032)
12.2.8.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Phases (2020-2032)
12.3.2. Market Revenue and Forecast, by Services (2020-2032)
12.3.3. Market Revenue and Forecast, by End User (2020-2032)
12.3.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Phases (2020-2032)
12.3.5.2. Market Revenue and Forecast, by Services (2020-2032)
12.3.5.3. Market Revenue and Forecast, by End User (2020-2032)
12.3.5.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Phases (2020-2032)
12.3.6.2. Market Revenue and Forecast, by Services (2020-2032)
12.3.6.3. Market Revenue and Forecast, by End User (2020-2032)
12.3.6.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Phases (2020-2032)
12.3.7.2. Market Revenue and Forecast, by Services (2020-2032)
12.3.7.3. Market Revenue and Forecast, by End User (2020-2032)
12.3.7.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Phases (2020-2032)
12.3.8.2. Market Revenue and Forecast, by Services (2020-2032)
12.3.8.3. Market Revenue and Forecast, by End User (2020-2032)
12.3.8.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Phases (2020-2032)
12.4.2. Market Revenue and Forecast, by Services (2020-2032)
12.4.3. Market Revenue and Forecast, by End User (2020-2032)
12.4.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Phases (2020-2032)
12.4.5.2. Market Revenue and Forecast, by Services (2020-2032)
12.4.5.3. Market Revenue and Forecast, by End User (2020-2032)
12.4.5.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Phases (2020-2032)
12.4.6.2. Market Revenue and Forecast, by Services (2020-2032)
12.4.6.3. Market Revenue and Forecast, by End User (2020-2032)
12.4.6.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Phases (2020-2032)
12.4.7.2. Market Revenue and Forecast, by Services (2020-2032)
12.4.7.3. Market Revenue and Forecast, by End User (2020-2032)
12.4.7.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Phases (2020-2032)
12.4.8.2. Market Revenue and Forecast, by Services (2020-2032)
12.4.8.3. Market Revenue and Forecast, by End User (2020-2032)
12.4.8.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Phases (2020-2032)
12.5.2. Market Revenue and Forecast, by Services (2020-2032)
12.5.3. Market Revenue and Forecast, by End User (2020-2032)
12.5.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Phases (2020-2032)
12.5.5.2. Market Revenue and Forecast, by Services (2020-2032)
12.5.5.3. Market Revenue and Forecast, by End User (2020-2032)
12.5.5.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Phases (2020-2032)
12.5.6.2. Market Revenue and Forecast, by Services (2020-2032)
12.5.6.3. Market Revenue and Forecast, by End User (2020-2032)
12.5.6.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
Chapter 13. Company Profiles
13.1. Thermos Fischer Scientific, Inc.
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Sharp Packaging Services
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Catalent Pharma Solutions
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Piramal Pharma Solutions
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. UDG Healthcare
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. PAREXEL International Corporation
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Almac Group Ltd.
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Movianto GmbH
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Patheon, Inc.
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Biocair International Ltd.
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 774 402 6168
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
0 Comments